Answers are grounded in this paper and cite their sources.
The COVID-19 outbreak has shown that the success of treatment is not only based on the drug’s inherent activity but also its capacity to get to the appropriate biological target at the right time and in a sufficient amount. Considering this, drug delivery systems based on nanotechnology have been gaining ground as potential platforms capable of overcoming formulation and drug delivery constraints related to many COVID-19 drugs, such as low solubility, instability, short half-life, limited access to the cell interior, and off-target toxicity affecting non-target cells. This piece of writing provides an overview of the main therapeutic approaches utilized during the COVID-19 crisis and aligns them with the delivery needs of various drug modalities, such as small molecules, biologics, nucleic acids, and combination therapies. Moreover, this review highlights the ability of nanoscale systems to enhance local exposure and minimize systemic exposure, coupled with the ability to control drug release and the impact of these nanosystems on pharmacokinetics and pharmacodynamics based on existing experimental and clinical data. Lung-targeted nanocarriers are the focus of this article, given the respiratory tract tropism of SARS-CoV-2. The rationale behind pulmonary delivery, aerosol deposition physics, lung biological barriers, and major safety issues are described and supported by nanocarrier properties for the lung and their applicability for SARS-CoV-2. In addition, the review discusses how nano-based systems can improve pharmacokinetics and pharmacodynamic performance by enhancing local drug exposure, reducing systemic distribution, and enabling controlled release. Finally, the quality of evidence from existing clinical studies is analyzed in detail, and important translational barriers hindering translation to clinical applications, such as good manufacturing practice compliant production, batch consistency, formulation-device compatibility, regulations, and scalability, are highlighted.
No takes yet. Share an insight, caveat, or question.
Elaibi et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: